|Bid||2.0100 x 4000|
|Ask||2.0200 x 45900|
|Day's Range||2.0000 - 2.0800|
|52 Week Range||1.7300 - 4.3000|
|Beta (3Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.67|
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.
OPKO Health, Inc. (OPK) today announced that the last patient has completed the final visit in the Company’s pivotal Phase 3 study evaluating the safety and efficacy of the once weekly somatrogon (hGH-CTP) for treatment of growth hormone deficiency in children. The study enrolled a total of 224 treatment naïve patients from 21 countries who were randomized 1:1 into two arms: once-weekly somatrogon vs. once-daily Genotropin® (somatropin). Secondary endpoints are safety and pharmacodynamic endpoints. The clinical safety and efficacy data are currently in the process of being compiled and validated prior to data base lock. “We are pleased to report the completion of the somatrogon pivotal study, an important milestone in the development of once weekly somatrogon.
OPKO Health (OPK) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
MIAMI, Aug. 07, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended June 30, 2019. Business Highlights.
Opko Health (NYSE: OPK ) unveils its next round of earnings this Wednesday, August 7. Here is Benzinga's everything-that-matters guide for the earnings announcement. Earnings and Revenue Analysts are predicting ...
MIAMI, Aug. 01, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) plans to report its operating and financial results for the three months ended June 30, 2019, as well as provide.
BioReference Laboratories, Inc., one of the largest clinical laboratories in the United States, today announced it has been selected by The IPA Association of America (TIPAAA) as its preferred provider of laboratory services and to assist with data analytics for its members’ patients. The agreement is designed to enhance patient care and offer collaborative health management tools to TIPAAA members, which includes more than 667 medical organizations representing over 303,000 MDs in 39 states. TIPAAA provides services that assist in improving the overall operations of Independent Physician Associations (IPAs) nationwide. Members will now have convenient access to BioReference’s comprehensive laboratory testing menu, including thousands of frequently requested routine and specialty tests, as well as the 4Kscore®, a blood test for detecting aggressive prostate cancer.
OPKO Health (OPK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Details the CEO buys this past week for the following companies: G-III Apparel Group, W&T; Offshore, HealthEquity, DXC Technology and OPKO Health Continue reading...
The largest Insider Buys this week were for Thor Industries Inc. (THO), Sinclair Broadcast Group Inc. (SBGI), OPKO Health Inc. (OPK), and Perspecta Inc. (PRSP). Continue reading...
OPKO Health (OPK) announced that its subsidiary, BioReference Laboratories, one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients. This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network. SOMOS is New York City’s largest multi-cultural physician-led network that serves predominately underserved patient populations.
BioReference Laboratories, Inc., an OPKO Health (OPK) company and one of the largest clinical laboratories in the United States, has been selected by SOMOS, a physician-led network of more than 2,500 health care providers serving over 700,000 Medicaid beneficiaries in New York City, as its preferred provider of diagnostic testing and to assist with data analytics for its patients. This new collaboration is designed to streamline patient care and offer communication efficiencies between BioReference and the SOMOS network.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination (LCD) for the 4Kscore® test, with defined coverage criteria. Under the LCD, Medicare will reimburse the test for patients who meet the defined criteria. The full text of the updated LCD can be found here.
OPKO Health, Inc. (OPK) announces that the Company has submitted a de novo request to the U.S. Food and Drug Administration (FDA) seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care professionals to assess a patient’s risk of having aggressive prostate cancer after an abnormal prostate specific antigen (PSA) test result, and before a decision is made to perform a biopsy. The de novo pathway for approval is available to medical devices of low-to-moderate risk that do not have an approved predicate device. Per FDA guidelines, the Company expects to receive a response to this request within approximately 180 days.